Videos
Expanding the Role of Immunotherapy in Triple-Negative Breast Cancer
03/18/2026
At Great Debates Solid Tumors in Miami, Florida, Yuan Yuan, MD, PhD, from Cedars-Sinai Medical Center, Pasadena, California, discusses whether all patients with triple-negative breast cancer should receive immunotherapy.
Dr Yuan highlights the persistent unmet need in this population, noting that outcomes remain poor after recurrence despite recent advances, and emphasizes the importance of expanding and personalizing immunotherapy approaches to address tumor heterogeneity and improve long-term outcomes.
Source:
Yuan Y. All patients with TNBC should receive immune checkpoint inhibitor therapy: Yes vs no. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
